[{"id":"544913f3-e7c0-4620-94d2-7b86fba5ea63","acronym":"","url":"https://clinicaltrials.gov/study/NCT05415098","created_at":"2022-06-10T12:58:54.863Z","updated_at":"2024-07-02T16:36:00.363Z","phase":"Phase 1","brief_title":"Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas","source_id_and_acronym":"NCT05415098","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" SMARCB1","pipe":" | ","alterations":" EZH2 mutation","tags":["SMARCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EZH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APG-5918"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 09/30/2022","start_date":" 09/30/2022","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2022-11-16"}]